Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1635
This examiner grants 52% of resolved cases
Africa Mhairie McLeod is assigned to Art Unit 1600 in Tech Center 1600. She has 52 resolved cases and an allowance rate of 51.9 percent. The median days to allowance is 1409. These figures describe the prosecution environment for this examiner and provide a basis for understanding the application lifecycle.
The interview lift is 67.5 percent. This metric indicates that an interview is associated with an increase in the probability of allowance. Practitioners facing the 51.9 percent allowance rate may consider the 67.5 percent lift when deciding whether to request an interview. The 1409 days median pendency provides a timeline for successful applications. With 52 resolved cases, the data indicates the duration of prosecution. The Art Unit 1600 and Tech Center 1600 designations are data points for strategy. This profile informs the approach for applications on this docket.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18253198 | Systems and Methods for Diagnostic Assessment and Treatment of Insulin Resistance and Hyperglycemia | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 17961925 | PREDICTION, BIOSYNTHESIS, AND INTEGRATION AS BIOSENSORS OF MOLECULES WITH UNIQUE LIGHT ABSORBANCE SIGNATURES AND THEIR SUBSEQUENT IN-FIELD REMOTE DETECTION USING MULTI OR HYPER-SPECTRAL CAMERAS | Final Rejection | Massachusetts Institute of Technology |
| 17761292 | NOVEL TYPE VI CRISPR ENZYMES AND SYSTEMS | Non-Final OA | MASSACHUSETTS INSTITUTE OF TECHNOLOGY |
| 18685204 | Nucleotides Comprising CasPhi Modified for Nuclear Targeting | Non-Final OA | Vanderbilt University |
| 17577942 | RECOMBINASE COMPOSITIONS AND METHODS OF USE | Final Rejection | Flagship Pioneering Innovations VI, LLC |
| 18253793 | INHIBITION OF KIR2DL2 FOR THE ENHANCEMENT OF ADOPTIVE IMMUNOTHERAPIES | Non-Final OA | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE INC. |
| 18006975 | IN UTERO AND POSTNATAL GENE EDITING AND THERAPY FOR TREATMENT OF MONOGENIC DISEASES, INCLUDING MUCOPOLYSACCHARIDOSIS TYPE 1H AND OTHER DISORDERS | Non-Final OA | THE CHILDREN'S HOSPITAL OF PHILADELPHIA |
| 17265302 | ALTERNATIVE SPLICING REGULATION OF GENE EXPRESSION AND THERAPEUTIC METHODS | Non-Final OA | THE CHILDREN'S HOSPITAL OF PHILADELPHIA |
| 18326440 | BASE EDITING ENZYMES | Non-Final OA | METAGENOMI, INC. |
| 17767340 | METHODS AND COMPOSITIONS FOR TREATING ATAXIA TELANGIECTASIA | Final Rejection | The Children's Medical Center Corporation |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy